21st Austria weekly - Valneva, FACC (13/11/2024)

17.11.2024

Valneva: Valneva SE, an Austrian/French specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Valneva obtained an exclusive worldwide license from LimmaTech.
Valneva: weekly performance: -9.69%

FACC: The continued strong growth of the aviation industry and the associated high demand for passenger aircraft continues in the third quarter of 2024. FACC AG is benefiting disproportionately strong from this growth trajectory and was able to increase its revenue by +25.1 % to EUR 642.6 million in the first nine months of the 2024 financial year (previous year: EUR 513.9 million). EBIT of EUR 21.8 million more than quadrupled year-on-year (previous year: EUR 5.0 million).
FACC: weekly performance: 7.49%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/11/2024)


Partners









latest 21st Austria

21st Austria weekly - Valneva, FACC (13/11/2024)


17.11.2024, 1143 Zeichen



Valneva: Valneva SE, an Austrian/French specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Valneva obtained an exclusive worldwide license from LimmaTech.
Valneva: weekly performance: -9.69%

FACC: The continued strong growth of the aviation industry and the associated high demand for passenger aircraft continues in the third quarter of 2024. FACC AG is benefiting disproportionately strong from this growth trajectory and was able to increase its revenue by +25.1 % to EUR 642.6 million in the first nine months of the 2024 financial year (previous year: EUR 513.9 million). EBIT of EUR 21.8 million more than quadrupled year-on-year (previous year: EUR 5.0 million).
FACC: weekly performance: 7.49%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/11/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 92/365: Ich beantworte 5 HörerInnen-Fragen zum Aktienmarkt so gut es geht, so weit ich darf (1)




 

Bildnachweis

Aktien auf dem Radar:Porr, FACC, DO&CO, Agrana, Frequentis, Pierer Mobility, Lenzing, Semperit, AT&S, CA Immo, Josef Manner & Comp. AG, Palfinger, Stadlauer Malzfabrik AG, Warimpex, Addiko Bank, Flughafen Wien, Oberbank AG Stamm, Zumtobel, RHI Magnesita, Austriacard Holdings AG, Amag, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG.


Random Partner

Matejka & Partner
Die Matejka & Partner Asset Management GmbH ist eine auf Vermögensverwaltung konzentrierte Wertpapierfirma. Im Vordergrund der Dienstleistungen stehen maßgeschneiderte Konzepte und individuelle Lösungen. Für die Gesellschaft ist es geübte Praxis, neue Herausforderungen des Marktes frühzeitig zu erkennen und entsprechende Strategien zu entwickeln.

>> Besuchen Sie 60 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten


h